Amphastar Pharmaceuticals Inc vs Lumen Technologies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.9 (market cap $868.62M), while Lumen Technologies Inc trades at $6.31 (market cap $6.58B). The key difference: Lumen Technologies Inc is far larger — about 7.6× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | LUMN | |
|---|---|---|
Market Cap | $868.62M | $6.58B |
Sector | Health | Media |
52-Week High | $30.81 | $11.83 |
52-Week Low | $16.87 | $3.95 |
Enterprise Value | $1.27B | $18.20B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
LUMN trades at $6.33, down 4.67% today, with a bearish technical signal and neutral oscillators. Revenue declined to $12.40B in 2025, with a net loss of $1.74B, though Q2 2026 earnings beat estimates. The company is shifting to digital services, with strategic revenues growing 14.1% in Q2 2026. High debt of $17.49B remains a concern, but positive cash flow from operations of $4.74B in 2025 supports liquidity.
Outlook is mixed: analyst consensus price target is $7.67 with a hold-heavy rating, indicating cautious optimism. Risks include persistent revenue declines and heavy debt load, but opportunities lie in digital transformation and AI-driven growth. CEO share purchases and institutional holdings suggest insider confidence amid challenges.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →